US · Healthcare · Biotechnology
EPS came in at -0.19 against a street estimate of -0.15 — a miss of 23.8%.
Analysts rate Iovance Biotherapeutics Inc a buy (8 buy, 4 hold, 0 sell out of 12) with an average price target of $8.22.
| Fund | Stake |
|---|---|
| BlackRock Inc | 6.96% |
| Mhr Fund Management Llc | 6.49% |
| State Street Corp | 3.91% |
| Vanguard Capital Management, LLC | 3.72% |
| Two Sigma Investments LLC | 3.07% |
| Vanguard Portfolio Management, LLC | 2.62% |
| Millennium Management LLC | 2.11% |
| The Goldman Sachs Group Inc | 1.96% |
| Document | Date |
|---|---|
| Company announcement · Q2 2026 | 2026-07-02 |
| Shareholder vote results · Q2 2026 | 2026-06-10 |
| Results announced · Q2 2026 | 2026-05-07 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Board / officer change · Q1 2026 | 2026-03-20 |
| Annual report FY2025 | 2026-02-24 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Iovance Biotherapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.